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Stress-responsive FKBP51 regulates AKT2-AS160
signaling and metabolic function
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The co-chaperone FKBP5 is a stress-responsive protein-regulating stress reactivity, and its
genetic variants are associated with T2D related traits and other stress-related disorders.
Here we show that FKBP51 plays a role in energy and glucose homeostasis. Fkbp5 knockout
(51KO) mice are protected from high-fat diet-induced weight gain, show improved glucose
tolerance and increased insulin signaling in skeletal muscle. Chronic treatment with a novel
FKBP51 antagonist, SAFit2, recapitulates the effects of FKBP51 deletion on both body weight
regulation and glucose tolerance. Using shorter SAFit2 treatment, we show that glucose
tolerance improvement precedes the reduction in body weight. Mechanistically, we identify a
novel association between FKBP51 and AS160, a substrate of AKT2 that is involved in glucose
uptake. FKBP51 antagonism increases the phosphorylation of AS160, increases glucose
transporter 4 expression at the plasma membrane, and ultimately enhances glucose uptake in
skeletal myotubes. We propose FKBP51 as a mediator between stress and T2D development,
and potential target for therapeutic approaches.
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FK506-binding protein 51 (FKBP51) is an immunophilinprotein best known as a negative regulator of the gluco-corticoid receptor (GR) and consequently the physiological
stress response1. Speciﬁcally, in complex with FKBP51 (FKBP5
gene), the GR displays reduced ligand afﬁnity, reduced nuclear
translocation, and ultimately decreased GR sensitivity1–5.
By contrast, in complex with its functional counter-player
FKBP52 (FKBP4 gene), GR activity is enhanced6. Single-
nucleotide polymorphisms (SNPs) in the FKBP5 gene, which
are associated with increased expression of FKBP5 (high-induc-
tion allele), have been fundamentally linked to stress-related
disorders, and most notably in psychiatric disorders7. In this
context, it is possible that stress-induced FKBP5 may similarly be
implicated in additional stress-related pathophysiologies, such as
type 2 diabetes (T2D).
Exposure to nutrient overload, including exposure to a high-fat
diet (HFD), is considered a metabolic stressor8. Interestingly, it
was reported that 8 weeks of HFD exposure in mice led to
enhanced Fkbp5 expression in the hypothalamus9, suggesting that
Fkbp5 is responsive to metabolic stressors and is able to sense the
nutrient environment. Accordingly, a study examining food
restricted-responsive genes reported an induction of Fkbp5 in the
hypothalamus and ventral tegmental area10. This is in agreement
with an earlier study, which used a 24-h food restriction paradigm
as a stressor to investigate stress-induced Fkbp5 expression across
multiple brain regions11.
There are several additional lines of evidence to support the
possibility that FKBP51 links stress to metabolic function. Human
adipocytes and skeletal muscle are among the tissues presenting
the strongest expression of FKBP512. Recently, the high-induction
FKBP5 risk allele was associated with reduced weight loss fol-
lowing bariatric surgery13. A genome-wide association study
furthermore demonstrated that SNPs within the FKBP5 gene loci
are associated with T2D and markers of insulin resistance14.
Preclinical studies in animal models have similarly demonstrated
that complete loss of FKBP51 protects against HFD-induced body
weight gain and hepatic steatosis, which is, in part, explained by
an increased expression of uncoupling protein 1 (UCP1), a spe-
ciﬁc marker of browning, in white adipose tissue (WAT) and
increased thermogenesis15. Additionally, FKBP51 is a negative
regulator of all 3 isoforms of the serine/threonine protein kinase
AKT (AKT1, AKT2, and AKT3), and through this action, reg-
ulates the response to chemotherapy16. AKT is also a central node
within the insulin signaling pathway, and deregulation of AKT
activation, most notably AKT2 activation, has been linked to the
pathogenesis of diabetes and obesity17, 18. In this context, FKBP51
may be an important regulator of insulin signaling and conse-
quently energy and glucose homeostasis19. Nevertheless, whether
FKBP51 plays a critical role in whole body glucose metabolism
remains to be elucidated. For this purpose, we aimed to char-
acterize the role of FKBP51 in energy and glucose homeostasis
using a combination of Fkbp5 knockout (51KO) mice,
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Fig. 1 Genetic ablation of FKBP51 prevents HFD-induced weight gain. a 51KO mice (n= 16) presented lowered body weight, decreased fat mass, and
increased lean mass compared to WT littermates (n= 18) at the onset of the dietary feeding period. b 51KO mice weighed signiﬁcantly less than WT mice
throughout the 8-week dietary treatment and at the experimental end (n= 9 WT-Chow, n= 9 WT-HFD, n= 9 51KO-Chow, n= 7 51KO-HFD). Whereas
WT mice were susceptible to HFD-induced weight gain, 51KO mice were not as interpreted from weight progression and ﬁnal body weight (following
8 weeks on respective diets). c After 8 weeks on the dietary treatment, 51KO mice presented decreased fat pad weights for epididymal (e), inguinal (i), and
perirenal (p) white adipose tissues (WAT) compared to WT counterparts whereas presented no change in brown adipose tissue (BAT) mass. HFD
exposure signiﬁcantly increased fat pad mass, regardless of genotype. Lean mass was adjusted for body weight and is expressed for a 30-g mouse. Data
are represented as mean± SEM. +P< 0.05, ++P< 0.01, +++P< 0.001; #P< 0.05, ##P< 0.01, ###P< 0.001, two-tailed t test for a, Repeated measures
ANOVA and two-way ANOVA for b, two-way ANOVA for c; + signiﬁcant genotype effect; # signiﬁcant diet effect
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01783-y
2 NATURE COMMUNICATIONS | 8:  1725 |DOI: 10.1038/s41467-017-01783-y |www.nature.com/naturecommunications
pharmacological manipulations, and mechanistic studies. We
found in this study that FKBP51 regulates glucose metabolism in
mice, through it, regulation of AKT2-AS160 signaling, glucose
transporter expression, and glucose uptake in myotubes. Phar-
macological antagonism of FKBP51 improves glucose tolerance,
irrespective of body weight changes, which suggests an oppor-
tunity to target FKBP51 for the treatment of T2D.
Results
FKBP51 loss opposes obesity and improves glucose tolerance.
In order to examine the role of FKBP51 in energy and glucose
homeostasis, we initially characterized the metabolic outcomes
arising in 51KO mice. We found that 51KO mice fed with a
standard chow diet showed a modest body weight reduction,
reduced adiposity, and increased lean mass compared to WT
littermates (Fig. 1a). When challenged with HFD exposure for
8 weeks, the 51KO mice were protected from both HFD-induced
weight gain and increased adiposity (Fig. 1b, c). Loss of FKBP51
likewise counteracted diet-induced obesity under thermoneutral
conditions (30 °C), arguing against a thermoregulatory basis of
the phenotype (Supplementary Fig. 1). Indirect calorimetry
revealed that the body weight phenotype observed in 51KO mice
under standard chow conditions was accompanied by a modest
increase in total energy expenditure, as a result of an increased
resting metabolic rate (RMR) (Supplementary Fig. 2A). In
addition, 51KO mice presented a modest decrease in their
respiratory exchange ratio (RER) and a slight increase in their
home-cage activity (Supplementary Fig. 2B, C). By contrast,
neither water nor food intakes were affected by loss of FKBP51
(Supplementary Fig. 2D, E). To conﬁrm a lack of FKBP51 effect
on feeding behavior, a separate pair-feeding experiment was
performed, in which a cohort of WT mice was pair-fed to 51KO
mice. This experiment again revealed no genotype effect on
energy intake (Supplementary Fig. 2G). Cold-induced body
temperature regulation was unaffected by FKBP51 genotype
(Supplementary Fig. 2H).
To determine the effects of FKBP51 on glucose metabolism
and insulin sensitivity, we performed glucose tolerance tests
(GTTs) and insulin tolerance tests (ITTs) in a separate cohort of
51KO and WT mice. The body weight data were consistent with
our previous experiments (Supplementary Fig. 3). FKBP51
deletion lowered fasting glucose (Fig. 2a) and remarkably
improved glucose tolerance (Fig. 2b, c). Although the effect of
FKBP51 deletion was present under the control condition, a
metabolic challenge using HFD exposure heightened the
genotype effect. Interestingly, the levels of fasted insulin and
glucose-stimulated insulin were not different between 51KO and
WT mice (Fig. 2d, e), indicating that differences in insulin
secretion do not contribute to the improved glucose tolerance
phenotype. In the ITT, 51KO mice presented a prolonged
response to insulin under control and HFD conditions, despite
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Fig. 2 Genetic ablation of FKBP51 improves glucose tolerance. a Blood glucose following a 14 h fast was signiﬁcantly lower in 51KO mice compared to WT
mice. b In the GTT, a HFD impaired glucose tolerance in WT mice but not in 51KO mice. c The glucose area under curve (AUC) illustrates the effect of
genotype and diet on glucose tolerance. d, e Fasted insulin and glucose-stimulated insulin were signiﬁcantly elevated from HFD exposure independent of
genotype. f In HFD-fed mice, loss of FKBP51 signiﬁcantly reduced insulin tolerance. Importantly blood glucose remained signiﬁcantly lower 120min
following insulin administration on account of FKBP51 deletion under both chow conditions and HFD conditions. g The glucose AUC for ITT demonstrates
the strong diet effect and a trend for genotype. n= 8 WT-Control, n= 10 WT-HFD, n= 12 51KO-Control, n= 13 51KO-HFD. Data are represented as mean
± SEM. +P< 0.05, ++P< 0.01, +++P< 0.001; #P< 0.05, ##P< 0.01, ###P< 0.001, TP< 0.1, two-way ANOVA for a, Repeated measures ANOVA for b, f,
two-way ANOVA for c–e and g; + signiﬁcant genotype effect; # signiﬁcant diet effect; T signiﬁcant trend for genotype
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the fact that both 51KO and WT mice remained vulnerable to
HFD-induced insulin intolerance (Fig. 2f, g).
FKBP51 antagonism rapidly improves glucose tolerance. Due
to the improved metabolic phenotype presented in 51KO mice,
we subsequently assessed the effects of pharmacological blockade
of FKBP51. Importantly, the ﬁrst highly selective antagonist for
FKBP51, SAFit2, has recently been developed20. In the current
study, we determined the efﬁcacy of FKBP51 antagonism in mice
on metabolic parameters. We examined the efﬁcacy of a single
application of SAFit2 gel (a slow release formulation, Supple-
mentary Fig. 4A), to improve glucose tolerance. Although SAFit2
gel had no effect in chow-fed mice measured at 48 h following
application (Fig. 3a, b), it signiﬁcantly improved glucose tolerance
in HFD-fed mice (Fig. 3c), supporting the literature demon-
strating that FKBP51-mediated outcomes are more robust under
challenging conditions21–25. The effect of SAFit2 treatment on
glucose tolerance is speciﬁc to FKBP51 inhibition, as no effect was
observed in 51KO mice under HFD conditions (Fig. 3d).
Importantly, body weight was not affected (Fig. 3e), arguing for a
body weight-independent effect of FKBP51 inhibition on glucose
tolerance. Acute SAFit2 treatment furthermore had no effect on
energy expenditure, respiratory exchange ratio, or activity counts
(Supplementary Fig. 4B–D). We also examined the expression of
UCP1 in brown adipose tissue (BAT) of mice treated for 48 h
with SAFit2 and found no effect of acute treatment (Supple-
mentary Fig. 4E). We then examined the effects of a sub-chronic
SAFit2 (20 mg kg−1) regimen administered twice daily for 10 days
to adult C57BL/6 mice by intraperitoneal injections under chow-
fed conditions. The dose was selected based on the effective dose
used in acute studies26. Using a 10-day treatment schedule, we
observed an effect of SAFit2 under chow diet conditions.
Speciﬁcally, although 10 days of FKBP51 antagonism again yiel-
ded no body weight phenotype, there was a marked improvement
of glucose tolerance assessed on treatment day 8 (Fig. 3e, f). The
lack of body weight change from either the acute or 10-day
SAFit2 treatment schedule indicates that the FKBP51-dependent
glucose tolerance phenotype is not secondary to the body weight
phenotype. To determine whether a longer treatment period
would replicate the body weight phenotype of 51KO mice, a new
cohort of C57BL/6 mice was treated with SAFit2 for 30 days
under both control and HFD conditions (for SAFit2 plasma levels
see Supplementary Fig. 5A). At the onset of treatment, following
4 weeks of dietary exposure, there was no difference in body
weight between the treatment groups (Supplementary Fig. 5B, C).
However, we found that 30 days of SAFit2 administration led to a
reduction in body weight under both control and HFD conditions
(Fig. 3g). FKBP51 antagonism furthermore protected against
HFD-mediated glucose intolerance (Fig. 3h). There was, however,
no effect of SAFit2 on insulin tolerance or on locomotor activity
tested in the open-ﬁeld test (Supplementary Fig. 5D, E). We
observed no unwanted side-effects of FKBP51 antagonism on
behavioral readouts tested in the dark–light transition and ele-
vated plus-maze tests (Supplementary Fig. 5F, G). Taken together,
these results clearly demonstrate that (i) a body weight phenotype
is secondary and not necessary for the effects of FKBP51 antag-
onism on glucose tolerance, and (ii) pharmacological blockade of
FKBP51 parallels the effects of FKBP51 genetic ablation.
FKBP51 loss sensitizes insulin signaling in skeletal muscle. As
the effect of FKBP51 on glucose tolerance was primary and
independent to the body weight phenotype, we addressed this
mechanism in the subsequent experiments. To unravel the
FKBP51-dependent regulation of glucose metabolism, we ﬁrst
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Fig. 3 FKBP51 antagonism parallels the metabolic effects resulting from genetic ablation of FKBP51. a A single application of a slow-release-formulated
SAFit2 gel had no effect on glucose tolerance or (b) Body weight under control diet conditions. c Under HFD conditions, acute administration of SAFit2 gel
signiﬁcantly improved glucose tolerance. d The effects of SAFit2 on glucose tolerance under HFD conditions were not present in 51KO. e Despite the
effects of acute SAFit2 on glucose tolerance under HFD conditions, there was no effect on body weight (f) 10-day SAFit2 treatment had no signiﬁcant
effect on body weight. g Despite no effect on body weight, SAFit2 treatment signiﬁcantly improved glucose tolerance as reﬂected in the glucose area under
the curve (AUC) for the GTT measured on treatment day 8. h At the experimental end point (following 30 days of treatment), mice treated with SAFit2
weighed signiﬁcantly less than their diet counterparts. Nevertheless, mice fed with the HFD remained signiﬁcantly heavier independent of treatment. i The
extended SAFit2 treatment schedule furthermore protected against HFD-induced impaired glucose tolerance as reﬂected in the glucose AUC measured on
day 25. For acute treatment schedule in C57BL6 n= 12 per treatment group; for acute treatment in 51KO n= 8 per treatment group. For the 10-day
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examined FKBP51 protein expression across multiple peripheral
tissues. Interestingly, FKBP51 was not ubiquitously expressed
across all tissues examined, but rather showed a deﬁned expres-
sion proﬁle. FKBP51 was detected within skeletal muscle (soleus
muscle and EDL) eWAT and iWAT (Supplementary Fig. 6A). By
contrast, FKBP51 was not detected in the liver, kidney, spleen,
pancreas, gut, or BAT. In addition, HFD exposure (for 8 weeks)
signiﬁcantly increased levels of FKBP51 in EDL skeletal muscle
(Supplementary Fig. 6B), and supports the notion that a high-fat
dietary environment acts as a metabolic stressor8, 27.
As a next step, we examined the phosphorylation status of
critical nodes along the insulin signaling cascade as a marker of
insulin signaling activation. As we found a strong effect of FKBP51
loss on glucose tolerance without any change in circulating insulin
levels, we hypothesized that intracellular insulin signaling is
enhanced following loss of FKBP51. Indeed, 5 min following
insulin stimulation (0.70 IU kg−1), we found that insulin sensitivity
(as reﬂected through the phosphorylation status of AKT2, AS160,
and p70S6K) was markedly increased in skeletal muscle (soleus
muscle and EDL) of 51KO mice (Fig. 4a, b), whereas insulin
activation in WAT (iWAT and eWAT) and liver remained
unchanged (Supplementary Fig. 7A, C). The skeletal muscle-
speciﬁc effect of FKBP51 deletion on insulin signaling is in line
with the high expression level of FKBP51 across skeletal muscle
tissues (reported above).
We subsequently assessed whether events downstream of
AKT2-AS160 signaling are likewise regulated by FKBP51.
Therefore, we ﬁrst examined glucose transporter GLUT4
translocation to the plasma membrane, which is triggered by
activated AKT2-AS160 signaling28. We isolated the plasma
membrane fraction from skeletal muscle extracted from WT and
51KO mice. 51KO mice display increased GLUT4 expression
compared to WT mice (Fig. 4c). There was no difference in
GLUT1 expression in the plasma membrane fraction between WT
and 51KO mice. Importantly, there was no effect of FKBP51
deletion either on total GLUT1 or GLUT4 expression (Supple-
mentary Fig. 7D). To assess the functional implications of these
FKBP51-dependent events, we examined radiolabeled-2-
deoxyglucose uptake in primary EDL myotubes collected either
from WT or 51KO mice. Glucose uptake was signiﬁcantly
increased by both insulin and FKBP51 deletion (Fig. 4d). More-
over, the effect of FKBP51 ablation on glucose uptake was
observed under both non-insulin and insulin-stimulated states,
indicating that FKBP51 deletion enhances glucose uptake
independent of the insulin state. In support of these ﬁndings,
overexpression of AKT2 enhanced glucose uptake in C2C12
myotubes (a mouse skeletal muscle cell line), whereas simulta-
neous overexpression with FKBP51 prevented the AKT2-mediated
enhanced uptake (Supplementary Fig. 8). Thus, FKBP51 acts
along the AKT2-AS160 signaling pathway to dampen glucose
uptake.
Given the effects of the FKBP51 antagonist, SAFit2, on glucose
tolerance in mice, we sought to further investigate whether SAFit2
modulates AKT2 activation and downstream events based on the
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known regulation of AKT2 by FKBP5116. We assessed pAKT2
and pAS160 in tissue collected from mice that had been pre-
treated with vehicle or SAFit2 6 h prior to tissue collection in
either an insulin-stimulated (0.70 IU kg−1 5 min before tissue
collection) or non-insulin (saline) condition. Although a single
intraperitoneal injection of SAFit2 applied 6 h before testing had
no effect on glucose tolerance (Supplementary Fig. 9), there was
already a signiﬁcant effect of SAFit2 treatment at a molecular
level. SAFit2 signiﬁcantly increased phosphorylated AKT2 and
AS160 in EDL muscle and likewise increased expression of
GLUT4 at the membrane in soleus muscle (Fig. 5a, b). Once
again, the effect of FKBP51 antagonism on pAKT2-pAS160 was
independent of the insulin-stimulated state. The same directional
change on phosphorylation states was observed in soleus muscle,
whereas this was not seen in eWAT (where FKBP51 expression is
relatively low) (Supplementary Fig. 10A, B). To ensure that the
effects of SAFit2 were selective for FKBP51, we additionally
examined the effects of SAFit2 treatment on pAKT2 and pAS160
in primary EDL and soleus myotubes from WT and 51KO mice.
While SAFit2 treatment increased the expression of pAKT2
(soleus and EDL muscle) and pAS160 (EDL muscle) in WT cells,
there was no effect of FKBP51 antagonism in 51KO cells,
conﬁrming the speciﬁcity of SAFit2 action (Supplementary
Fig. 10C, F). Moreover, following SAFit2 treatment, GLUT4
expression increased in the membrane fraction of primary EDL
myotubes from WT mice, but not from 51KO mice (Fig. 5c, d).
Finally, we applied SAFit2 to primary EDL myotubes and
measured radiolabeled-2-deoxyglucose uptake. FKBP51
antagonism-increased glucose uptake in EDL cells collected from
WT mice, but not 51KO mice, again demonstrating the speciﬁcity
of SAFit2 (Fig. 5e, f). Taken together, FKBP51 antagonism
increases AKT2-AS160 signaling, GLUT4 expression at the
plasma membrane, and glucose uptake into primary myotubes.
From these results, and based on previous literature high-
lighting a role of FKBP51 as a scaffolding protein16, 21, 29, we
assessed whether FKBP51 forms a complex with AS160 and
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furthermore assessed whether SAFit2 modulates this interaction.
Immunoprecipitation reactions, using protein extracts from 30-
day vehicle-treated and SAFit2-treated mice, revealed that SAFit2
treatment strengthened the binding between AKT2 and AS160
(Fig. 6a, b, bottom). This is in line with increased glucose uptake
given that AKT2 inactivates AS160, which in turn stimulates the
translocation of GLUT4 to the plasma membrane28. We
furthermore observed a novel interaction between FKBP51 and
AS160, and conﬁrmed that SAFit2 disrupts this interaction
(Fig. 6a, b, top). SAFit2, by contrast, had no effect on the binding
strength between AKT2 and PHLPP1 (the negative regulator of
AKT2). We conﬁrmed that the phosphorylation state of AKT2
and AS160 does not interfere with the interaction between
FKBP51 and either AKT2 or AS160 by also examining pAKT2
and pAS160. Co-immunoprecipitation does not discriminate
between direct and indirect protein interactions, and it is possible
that intermediate proteins are also involved in the interaction
between FKBP51 and AS160. Regardless, these ﬁndings suggest
that FKBP51 associates (directly or indirectly) with AS160 to
reduce glucose uptake. By contrast, SAFit2 antagonizes FKBP51
and reduces the binding between FKBP51 and AS160 to promote
a steric arrangement that favors glucose uptake.
We have shown that FKBP51 regulates insulin signaling
selectively in skeletal muscle. Yet FKBP51 is nonetheless
expressed in select WAT depots, albeit at lower levels. In order
to account for the tissue-speciﬁc effects of FKBP51, we
furthermore investigated the expression proﬁle of FKBP52, a
structural homolog of FKBP51 that competes as a scaffolding
protein, resulting in opposite functional effects30. Interestingly,
the expression proﬁle between FKBP51 and FKBP52 across
WATs and skeletal muscle are very distinct and provide an
explanation for the FKBP51 skeletal muscle-selective effects.
Speciﬁcally, FKBP51 expression is relatively high in skeletal
muscle compared to WATs (Supplementary Fig. 6A). In stark
contrast, levels of FKBP52 are high in WAT depots relative to
skeletal muscle. (Supplementary Fig. 11A). We additionally
performed co-immunoprecipitation reactions with FKBP52 to
investigate whether FKBP51 and FKBP52 compete for binding to
AKT2. We demonstrate that similar to FKBP51, FKBP52 is in
complex with AKT2 and AS160 (Supplementary Fig. 11B).
However, FKBP52 does not likewise interact with PHLPP1
(Supplementary Fig. 11B), the negative regulator of AKT2, and
consequently has divergent effects on downstream AKT2
signaling. Speciﬁcally, where ectopic overexpression of FKBP51
signiﬁcantly decreased pAKT2 and pAS160 expression in C2C12
myotubes, simultaneous overexpression of FKBP52 abolished the
effects of ectopic FKBP51 (Supplementary Fig. 10C). Taken
together, FKBP51 and FKBP52 compete for binding with AKT2.
The distinct expression proﬁle and functional outcomes of
FKBP51 and FKBP52 are responsible for the skeletal muscle-
speciﬁc effects of SAFit2, which selectively antagonizes FKBP51.
Discussion
Here we describe that loss of FKBP51 in mice markedly improves
metabolism and especially improves glucose tolerance under both
control and HFD conditions. This is in line with earlier pre-
clinical and human studies, which identiﬁed an association
between FKBP51 ablation and FKBP5 SNPs on traits related to
body weight regulation and T2D, respectively14, 15. Although the
effects of FKBP51 loss are witnessed under dietary control con-
ditions, the effects are signiﬁcantly accentuated when mice are
challenged to an HFD, which acts as a metabolic stressor8. This
supports a large body of literature, demonstrating that an
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Supplementary Fig. 15 shows uncropped gel images
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environmental challenge is a prerequisite for FKBP51-mediated
outcomes. For example, early life trauma (i.e., environmental
challenge) increases the risk of various psychiatric disorders
selectively in FKBP5 risk allele carriers, which are associated with
increased FKBP51 protein levels7, 24, 25, 31–33. In rodent studies,
51KO mice present no overt phenotype under basal conditions,
yet show improved stress resilience following either acute stress23
or chronic stress22. Indeed, stressors induce FKBP5 expression,
and this may underlie the more pronounced effects of FKBP51
deletion on metabolic phenotypes seen in the current study. We
certainly found that an HFD increases levels of FKBP51 in fat and
skeletal muscle. Taken together, previous ﬁndings have found that
higher levels of FKBP51 are associated with poorer outcomes in
stress-related psychiatric disorders. The present study shows that
higher levels of FKBP51 are likewise detrimental to metabolic
health, especially when confronted with environmental challenges
(i.e., an obesogenic environment).
Selective pharmacological antagonism of FKBP51 has only
recently been realized20. Selectivity for FKBP51 is especially
important since its structural homolog, FKBP52, acts as a func-
tional opponent. In fact, it was this structural similarity that
initially hampered drug discovery for FKBP51. The current ability
to antagonize FKBP51 offers new opportunities for drug devel-
opment. To date, only three studies have investigated the effects
of FKBP51 antagonism on functions related to FKBP51, and no
study has yet been investigated for long-term (i.e., 30 day)
applicability. These previous studies independently found that
FKBP51 antagonism induces anxiolytic effects26, reduces the
severity of pain symptoms34, and opposes the known ability of
FKBP51 to promote NFκB signaling35. Nevertheless, FKBP51 is a
multi-domain protein36, and it remains unknown whether the
FKBP51 antagonist, SAFit2, blocks all functions of FKBP51.
Therefore, in order to address whether pharmacological antag-
onism affects metabolic function, mice were treated with SAFit2
once (slow release formula) or repeatedly for either 10 or 30 days.
Administration of SAFit2 paralleled the metabolic phenotype
arising from total genetic loss of FKBP51. Acute SAFit2 treatment
improved glucose tolerance under metabolically challenging
conditions (i.e., HFD conditions). Under metabolic control con-
ditions (i.e., regular diet), FKBP51 blockade improved glucose
tolerance as early as 8 days following treatment onset. Impor-
tantly, the effects of FKBP51 modulation on glucose tolerance
were not secondary to changes in body weight since neither a
single nor a 10-day SAFit2 exposure had an effect on body weight.
It is possible that our study was underpowered to detect the
modest effects of SAFit2 treatment on body weight, since the 10-
day SAFit2-treated group showed a lower (non-signiﬁcant) body
weight phenotype compared to the vehicle-treated counterparts.
Regardless, these data support our studies in 51KO mice, which
collectively indicate that FKBP51 is an integral component of
glucose homeostatic regulation, particularly in response to
nutritional changes. In the context of body weight regulation, our
ﬁndings that 30 days of SAFit2 treatment protects against HFD-
induced weight gain supports the ﬁndings of a recently published
paper demonstrating that 51KO mice resist HFD-induced weight
gain and present increased UCP1 in WAT15. One limitation of
our study is that we do not know the minimal effective dose of
SAFit2 required to improve glucose tolerance. Nevertheless, the
improved metabolic outcomes following systemic administration
of the selective FKBP51 antagonist clearly demonstrate the
applicability in a clinical setting.
It is well established that FKBP51 is able to regulate many
signaling pathways through direct protein–protein interactions16,
21, 37, 38. Through these interactions, FKBP51 has been implicated
in various disease states (i.e., cancers, psychiatric disorders) and
in the response to medications (i.e., chemotherapies,
antidepressants). For example, through the FKBP51-dependent
regulation of AKT, Pei et al. (2009) reported that FKBP51 reduces
tumor growth16. FKBP51 binds to both AKT1 and AKT2 iso-
forms and their corresponding negative regulators PHLPP2 and
PHLPP1, to ultimately favor Akt inactivation. Interestingly, while
Akt1 is best known for its regulation of cell growth39, 40, AKT2 is
best known for its regulation of glucose homeostasis17, 41.
Accordingly, in the present study, we determined that FKBP51 is
also important for glucose disposal through the regulation of
AKT2 and downstream AS160 (AKT substrate of 160 kDa), an
important signaling protein involved in insulin-stimulated glu-
cose transport in skeletal muscle28, 42. 51KO mice exhibit
enhanced insulin signaling, as interpreted from the increased
phosphorylation of AKT2, AS160, and p70S6K. Interestingly, the
FKBP51-dependent effects on insulin signaling observed in mice
were highly tissue-speciﬁc, in which FKBP51-dependent increases
in insulin signaling was limited to skeletal muscle. Indeed, skeletal
muscle accounts for an estimated 80% of postprandial glucose
disposal and is regarded as a principal site responsible for the
maintenance of glucose homeostasis43, 44. In this context, we also
found that primary EDL myotubes from 51KO mice exhibited
heightened glucose uptake compared to WT EDL myotubes.
Ectopic FKBP51 overexpression furthermore completely reversed
the enhanced glucose uptake arising from AKT2 overexpression
in cultured myotubes, demonstrating that FKBP51 regulation of
insulin signaling is critical for glucose uptake.
The FKBP51-dependent effects on the phosphorylation of
AKT2 and AS160 as well as on glucose uptake were evident under
both non-insulin- and insulin-stimulated states, suggesting that
FKBP51 acts independent of insulin to improve glucose uptake
and whole body glucose homeostasis. Follow-up studies should
address whether FKBP51 is involved in insulin-independent
glucose uptake through the regulation of auxiliary pathways. For
example, AMP-activated protein kinase (AMPK) is a well-known
regulator of insulin-independent glucose uptake, leading to
increased AS160 phosphorylation and GLUT4 translocation in
the skeletal muscle45, 46. Furthermore, glucocorticoids are potent
regulators of glucose homeostasis, and they have been shown to
reduce insulin-stimulated glucose transport in muscle by blocking
the recruitment of GLUT4 to the cell surface47. Indeed, FKBP51
is known to reduce glucocorticoid receptor sensitivity1, and
therefore glucocorticoid signaling is another strong candidate
pathway by which FKBP51 may regulate whole body glucose
homeostasis. The data herein nevertheless provide unequivocal
evidence that FKBP51 is a novel regulator of AKT2-AS160 sig-
naling and glucose uptake.
Not only did FKBP51 antagonism parallel the metabolic phe-
notype arising from FKBP51 deletion, but it furthermore paral-
leled the molecular events induced by FKBP51 loss. SAFit2
treatment strongly induced AKT2 and AS160 phosphorylation
and led to increased GLUT4 expression at the plasma membrane.
Although we suspect that enhanced plasma membrane GLUT4
expression arises from pAKT2-pAS160-mediated increased
GLUT4 translocation to the membrane, it is possible that SAFit2
treatment also increases the total expression level of GLUT4. At a
functional level, SAFit2 heightened glucose uptake assessed in
primary muscle cells. Importantly, SAFit2 action on glucose tol-
erance and glucose uptake was highly speciﬁc for FKBP51 since
neither 51KO mice nor primary muscle cells collected from 51KO
mice responded to SAFit2 treatment. The robust effects of
FKBP51 antagonist SAFit2 on whole body glucose homeostasis
and skeletal muscle glucose uptake led us to examine whether
SAFit2 disrupts the well-characterized interaction between
FKBP51, AKT2, and PHLPP116. To our surprise we found no
effect of SAFit2. Rather, we discovered a novel interaction
between FKBP51 and AS160, which can be disrupted by FKBP51
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antagonism using SAFit2. This agrees nicely with our ﬁndings
that SAFit2 treatment increases glucose uptake in primary myo-
tubes and improves glucose tolerance in mice. Moreover this
supports accumulating evidence that FKBP51 has important
scaffolding properties to organize and concentrate various sig-
naling complexes16, 21, 37.
An important question raised by this study is how exactly
FKBP51 acts within distinct cellular/tissue environments to affect
whole body energy and glucose homeostasis. Previous studies
have already alluded to the importance of tissue-speciﬁc actions
of FKBP5126, 48. Here we extend our current understanding of the
tissue-speciﬁc actions of FKBP51 to include FKBP51-dependent
regulation of insulin signaling exclusively within skeletal muscle.
Despite microarray-based data demonstrating that skeletal muscle
shows the second strongest expression proﬁle of FKBP5 across all
tissues examined12, 14, to our knowledge, the current study is the
ﬁrst to deﬁne a skeletal muscle-speciﬁc role for FKBP51. The
distinct expression proﬁles of FKBP51 and FKBP52 provide an
explanation as to why FKBP51 affects glucose uptake exclusively
within skeletal muscle. Although FKBP52 shows strong
expression in WAT, it is expressed minimally in skeletal muscle.
We found that FKBP52 competes with FKBP51 for binding to
AKT2 in WAT, but this competition is minimal in skeletal muscle
based on its expression proﬁle. Importantly, although FKBP52 is
found in complex with AKT2 and AS160, it is not found to
interact with the negative regulator of AKT2, PHLPP1, and thus
does not have the same functional implications on downstream
AKT2 signaling compared to FKBP51.
Our study focused on the effects of FKBP51 modulation on
glucose homeostasis and pAKT2-pAS160 signaling, effects which
were independent of body weight. Nevertheless, we also reported
that 51KO mice are resistant to diet-induced obesity, present a
higher resting metabolic rate, and a slight increase in home-cage
activity. In support of these ﬁndings, a recent report demon-
strated that UCP1 expression is enhanced in select WAT depot in
51KO mice, which contributes to the improved body weight
phenotype15. Our ﬁnding that 51KO mice also presented
increased home-cage activity may furthermore underlie the
improved body weight phenotype. Although we found no dif-
ference in activity-related energy expenditure, the increased
activity in 51KO mice suggests that 51KO mice may have
increased exercise efﬁcacy. Follow-up studies are needed to
address such effects of FKBP51 on exercise efﬁcacy.
Our working model (Fig. 7) is that FKBP51 scaffolds AKT2,
PHLPP1, and AS160 (both phosphorylated and unpho-
sphorylated states), thereby enhancing PHLPP1 phosphatase
activity towards AKT2 (at Ser473). Accordingly, higher levels of
FKBP51, as is observed under HFD conditions, favors PHLPP1-
mediated inactivation of AKT2, activation of AS160, and ulti-
mately lower glucose uptake. Loss of FKBP51 results in AKT2
hyperactivation due to the loss of FKBP51’s scaffolding function.
Interestingly, in the presence of SAFit2, FKBP51 is no longer able
to form a complex with AS160; meanwhile, the AKT2-AS160
binding is enhanced. Consequently, SAFit2 treatment favors a
steric conﬁrmation that promotes glucose uptake. In summary,
we are the ﬁrst study to describe a mode of action for SAFit2.
Here, the ability of SAFit2 to oppose FKBP51-dependent glucose
uptake relates to the disruption of the AS160-FKBP51 complex.
Future studies are needed to delineate the full extent of SAFit2
action.
Together, this study deﬁnes a novel role for FKBP51 in the
regulation of glucose uptake and whole body glucose homeostasis.
Furthermore, we established a deﬁned molecular target linking
the stress system to the metabolic system, such that FKBP5
induction in response to metabolic stress contributes to the
metabolic fate of an individual. Our ﬁndings suggest that
FKBP51-dependent regulation of AKT2-AS160 signaling con-
tribute to improved glucose tolerance. In addition, we report the
ﬁrst long-term treatment study to employ the recently developed
FKBP51 antagonist SAFit2. The positive effects of FKBP51
antagonism on glucose tolerance reported here suggest the
opportunity to develop FKBP51 antagonists for the clinic, espe-
cially for the treatment of stress-related T2D.
Methods
Animals and animal housing. The Fkbp5 knockout (51KO) mouse line, used in
experiments 1, 2, and 3, had been previously generated49. C57BL/6 mice were used
in experiment 4 for the pharmacological blockade of FKBP51 (Charles River
Laboratories, Maastricht, The Netherlands). For all experiments, male mice
between 3 and 4 months old were used. During each experiment, the mice were
singly housed. The mice were maintained on a 12:12 h light/dark cycle, with
controlled temperature (22 +/− 2 °C) and humidity (55 +/− 5%) conditions. The
mice received ad libitum access to water and standard lab chow, unless otherwise
speciﬁed. The experiments were carried out in accordance with the European
Communities’ Council Directive 2010/63/EU. The protocols were approved to be
carried out at the Max Planck Institute of Psychiatry (license holder) by the ethical
committee for the Care and Use of Laboratory animals of the Government of
Upper Bavaria, Germany.
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Fig. 7 Proposed model of FKBP51 as a regulator of glucose uptake.
FKBP51 scaffolds Akt2, PHLPP1, and AS160. The associations between
FKBP51, AKT2, PHLPP1, and AS160 may be either direct or indirect through
additional intermediate proteins. In the presence of FKBP51, PHLPP1
phosphatase activity is directed towards AKT2 to favor inactive Akt2,
decreased AS160 phosphorylation and reduced glucose uptake. By contrast,
loss of FKBP51’s scaffolding function leads to increased AKT2. In the
presence of SAFit2, a conformational change within FKBP51 disrupts its
ability to form a complex with AS160, while simultaneously enhancing
AKT2-AS160 binding. Ultimately, loss of FKBP51 and FKBP51 antagonism
with SAFit2 both promote glucose uptake. “?” refers to possible
unidentiﬁed intermediate proteins within the FKBP51 signaling complex.
Curved arrows indicate PHLPP1-mediated dephosphorylation of AKT2 at
Ser473. The green double arrow indicates enhanced binding between AKT2
and AS160. Green outlines reﬂect enhanced phosphorylation; red outlines
reﬂect decreased phosphorylation. The width of the arrows correspond to
the magnitude of downstream activation
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Indirect calorimetry and body composition. The direct effects of FKBP51 deﬁ-
ciency on metabolic parameters were investigated using 51KO (n = 16) and wild-
type (WT) (n= 18) mice. Body composition (fat and lean mass) was assessed using
whole body magnetic resonance imaging (Echo-MRI, Houston, TX). Thereafter,
the mice were surgically implanted with a telemetric transponder (Respironics,
Murrysville, PA) for the measurement of core body temperature. The mice were
allowed to recover for approximately 2 weeks before any metabolic recordings were
performed. Indirect calorimetry and telemetry were performed on mice under
chow conditions (TSE PhenoMaster, TSE Systems, Bad Homburg, Germany). For
experimental details, see Supplemental Information. Each genotype group was
subsequently divided into a chow diet and high-fat diet (HFD) (58% kcal from fat,
D12331, Research Diets, New Brunswick, NJ, USA) group, matched for body
weight. Body weight was measured throughout the experiment. After 8 weeks on
the respective diets, 51KO and WT mice were killed. Epididymal (e), inguinal (i),
and perirenal (p) WAT were collected and weighed; brown adipose tissue (BAT)
was collected and weighed.
Thermoregulation. Body weight and body composition were examined in 51KO
and WT mice (n = 8 per genotype) under HFD conditions at 30 °C to minimize the
effects of thermal stress. A separate cohort of 51KO and WT mice were exposed to
6 h of cold exposure (4 °C) to assess cold-induced thermoregulation under both
control and HFD conditions (see Supplemental Information).
Pair-feeding. To assess the contribution of food intake on body weight regulation
in 51KO and WT mice, a pair-feeding experiment was performed. For experi-
mental details, refer to Supplemental Information.
Glucose tolerance and insulin tolerance. Glucose tolerance and insulin tolerance
were investigated in 51KO (n= 25) and WT mice (n = 18). Brieﬂy, 51KO and WT
mice were initially divided into a control diet group and an HFD group, matched
for body weight. After 8 weeks on the dietary treatment, the mice were subjected to
a glucose tolerance test (GTT). Additionally, blood was collected to assess fasting
insulin and glucose-stimulated insulin levels. One week thereafter, an insulin tol-
erance test (ITT) was performed. See Supplemental Information for more details.
SAFit2 administration. To determine whether antagonizing FKBP51 may be an
effective anti-obesity and/or diabetic therapeutic strategy, we treated mice with an
antagonist of FKBP51, known as SAFit220. SAFit2 or vehicle was administered
either acutely as a slow releasing vesicular phospholipid gel (VPG) (2 mg SAFit2 or
vehicle) or repeatedly by intraperitoneal (i.p.) injections (20 mg kg−1 SAFit2 or
vehicle) twice daily. For i.p. injections, SAFit2 was solubilized in vehicle containing
4% ethanol, 5% Tween80, and 5% PEG400 in 0.9% saline. Body weight and food
intake were measured daily throughout the treatment periods. VPGs were com-
posed of 50% (m/m) egg-lecithin containing at least 80% phosphatidylcholine
(Lipoid E80, Lipoid GmbH, Ludwigshafen, Germany) and 10 mM phosphate
buffered saline (PBS), pH 7.4, and were prepared by a dual asymmetric cen-
trifugation technique50. SAFit2 was encapsulated in the formulation by a direct
incorporation method. See Supplemental Information for more details.
Acute SAFit2 treatment. Male C57BL/6 mice were divided into vehicle-treated
and SAFit2-treated groups matched for body weight (n = 12 per group). On
treatment day 1, mice were administered (subcutaneous injection between the
shoulders) a slow release-formulated gel containing either SAFit2 or vehicle. After
48 h, a GTT was performed following an overnight fast.
Sub-chronic SAFit2 treatment. One day before the treatment period, male
C57BL/6 mice were divided into a vehicle-treated group and a SAFit2-treated
group matched for body weight (n= 8 per group). On treatment day 7, locomotor
activity was assessed in the open ﬁeld test. On treatment day 8, a GTT was per-
formed. SAFit2 levels were assessed in plasma from blood taken at the time of
killing. The animals were killed on day 10 following the treatment onset.
Chronic SAFit2 treatment. Four weeks before treatment onset, male C57BL/6
mice were divided into a control diet group (n= 25) and an HFD group (n= 25)
matched for body weight. One day before the treatment period, mice of each
dietary group were further subdivided into a vehicle-treated group and a SAFit2-
treated group matched for body weight. SAFit2 or vehicle were administered twice
daily for 30 days. On treatment days 10 and 30, SAFit2 levels were assessed in
plasma. The open ﬁeld, dark–light transition, and elevated plus-maze behavioral
tests were performed on treatment days 15, 16, and 17, respectively. The GTT was
performed on treatment day 25 and the ITT on treatment day 29. The animals
were killed on day 31 following treatment onset; tissues were collected and stored at
−80 °C for further analyses.
Tissue collection. Mice were anesthetized with isoﬂurane and immediately killed
by decapitation. Basal trunk blood was collected and subsequently processed
(plasma was collected and stored at −20 °C). Skeletal muscle (extensor digitorum
longus (EDL) and soleus), WAT (iWAT, eWAT, and pWAT), and liver were
collected and stored at −80 °C until used.
Cell lines. C2C12 myoblasts were maintained in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum and 1x penicillin
streptomycin antibiotics at 37 °C in a humidiﬁed atmosphere with 5% CO2. Once
the cells reached ~90% conﬂuency, C2C12 myoblasts were detached from the plate
and 2 × 106 cells were re-suspended in 100 µl of transfection buffer (50 mM HEPES
[pH 7.3], 90 mM NaCl, 5 mM KCl, and 0.15 mM CaCl2). A total of 2.5 µg of
plasmid DNA was used per transfection. Plasmids expressing AKT2-HA and
FKBP51-FLAG or GFP (control) have been described previously21, 51. Ectopic
overexpression of AKT2 and FKBP51 resulted in a 3.2-fold and 2.8-fold increase in
their expression, respectively. Electroporation was performed using the Amaxa
Nucleofector system (program #T-032). The cells were re-seeded onto 0.75%
gelatin-coated 12-well plates at a density of ~ 105 cells per cm2. Transfected cells
were induced to differentiate once they reached 90% conﬂuency. Differentiation
was induced by switching the growth medium to DMEM containing 2% horse
serum for 3 days.
Primary EDL myotubes were prepared from satellite cells collected from soleus
muscle and EDL myoﬁbers of 4- to 8-week old WT and 51KO mice as described
previously52. Brieﬂy, dissected muscles were washed in warm 1 x PBS and
subsequently were digested in Collagenase 1 at 37 °C for 1.5 h. Thereafter, single
ﬁbers were washed in DMEM with 1% P/S. After washing, the ﬁbers were
transferred to a 60mm plate (coated with 0,75% gelatin) and were allowed to
incubate at 37 °C for 3 days in growth medium (DMEM + 20% FBS + 1%P/S). The
satellite cells were detached from the plate and were re-plated onto 24-well multi-
well dishes. The medium was exchanged every 2–3 days and cells were split at
90–100% conﬂuency. Differentiation was induced by switching the growth medium
to DMEM containing 5% horse serum for 5 days.
Glucose uptake. Primary EDL myotubes or transfected C2C12 myotubes were
used for glucose uptake experiments. For SAFit2 experiments, a toxicity assay was
initially performed to determine the appropriate SAFit2 concentration for sub-
sequent experiments. Based on a lethal dose of 15 (LD 15), the cells were incubated
with 0.6 µM SAFit2 or DMSO overnight before inducing glucose uptake.
Basal and insulin-stimulated glucose uptake in primary EDL muscle cells and
differentiated C2C12 myotubes was examined. Brieﬂy, the cells were serum-starved
in low glucose (1000 mg L−1) DMEM for 4 h, and then incubated in Krebs–Ringer-
HEPES (KRH) buffer (136 mM NaCl, 4.7 mM KCl, 10 mM sodium phosphate
buffer, 1 mM MgSO4, 1 mM CaCl2, and 10 mM HEPES, pH 7.4, 0.2% BSA) for 10
min. The cells were stimulated with insulin (100 nM) or left unstimulated for 1 h.
Glucose uptake was induced by the addition of KRH buffer containing 100 µM 2-
deoxy-D-[1,2-3 H]glucose, 2 µCi ml−1 (Perkin Elmer) to each well. After 4 min, the
reactions were terminated by washing the cells with ice-cold PSB containing 10 µM
cytochalasin B (inhibitor of membrane transporter-dependent glucose transport),
and then 2 additional washes with ice-cold 1x PBS. Cells were lysed with 0.1 M
NaOH for 30 min, and the incorporated radioactivity was determined by liquid
scintillation counting. 2-deoxy-D-[1,2-3 H]glucose uptake was furthermore
normalized to total protein content assessed by the BCA assay (BCA Protein Assay
Kit, Life Technologies, Darmstadt, Germany).
Antibodies. Detailed information on antibodies and dilutions is provided in
Supplementary Information.
GLUT4 membrane localization. Primary EDL myotubes were exposed to 0.6 µM
SAFit2 or DMSO (vehicle) overnight. The following day, cells were serum-starved
in low glucose (1000 mg L−1) DMEM for 4 h with SAFit2 or DMSO, and were
subsequently collected for the rapid preparation of the plasma membrane fraction
as described previously53. The membrane fraction was used in subsequent Western
blot assays for the detection of GLUT4. For quantiﬁcation, GLUT4 was normalized
to both Na,K,ATPase (plasma membrane marker) and normalized total GLUT4, as
described previously54.
For GLUT4 membrane localization in 51KO (n= 6) and WT (n = 5) mice, the
mice were fasted for 6 h. Insulin was injected by i.p. administration (0.70 IU kg−1)
5 min before mice were anesthetized with isoﬂurane, and were immediately killed
by decapitation. Tissues were collected and stored at −80 °C until used. 2-way
subcellular fractionation was performed as described previously55.
Co-immunoprecipitation (coIP). Immunoprecipitations of endogenous proteins
were performed using protein extracts (n= 3 per group) from soleus muscle, EDL,
and eWAT of vehicle-treated and SAFit2-treated mice that were fed HFD. The
CoIP experiments were performed with beads conjugated with rabbit IgG. Brieﬂy,
500 µg of lysate was incubated overnight with 2 µg of the appropriate IP-antibody
(AKT2 (CST, #2964); FKBP5/FKBP51 (Bethyl, A301-430); and FKBP4/FKBP52
(Bethyl, A301-427A) (See Supplementary Table 1) at 4 °C. 20 µL of protein G
dynabeads (Invitrogen, 100-03D) was blocked with bovine serum albumin and
subsequently added to the lysate-antibody mix and allowed to incubate at 4 °C for
3 h in order to mediate binding between the dynabeads and the antibody-antigen
complex of interest. The beads were washed three times with ice-cold PBS. The
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protein-antibody complexes were eluted with 60 µL Laemmli loading buffer.
Thereafter, the eluate was boiled for 5 min at 95 °C. Then 2–5 µL of each immu-
noprecipitate reaction product was separated by SDS-PAGE and electro-
transferred onto nitrocellulose membranes. For assessing protein complexes,
immunoblotting against AKT2, FKBP51, PHLPP1 (Millipore, #07-1341), and
AS160 was performed. See Supplemental Information ‘Western blot analysis’ for
details.
Statistical analysis. Data were analyzed using IBM SPSS Statistics 18 software
(IBM SPSS Statistics, IBM, Chicago, IL, USA). The decomposition of total energy
expenditure (TEE) into activity-related energy expenditure (AEE) and resting
metabolic rate (RMR) was performed in MATLAB (The MathWorks, Natick, MA,
USA) using a custom-designed toolbox graciously provided by JB van Klinken
(Leiden University Medical Center, Leiden, The Netherlands). Body weight was
included as a covariate in the analyses of energy expenditure56. Statistical analyses
for all energy expenditure outcome variables, respiratory exchange ratio (RER),
home-cage activity, food intake, water intake, and body temperature were per-
formed on 24-hour averages. Statistical signiﬁcance was set at p < 0.05; a statistical
tendency was set at p< 0.1. For interactions at p < 0.1, we also examined lower
order main effects. Data are presented as the mean +/− SEM.
Data availability. The data herein are available from the corresponding authors
upon reasonable request.
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